SEC Form 4 · accession 0000899243-17-018767
INFINITY PHARMACEUTICALS, INC. · INFI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Adelene Q Perkins
Officer — Chief Executive Officer · Director
Period of report
Jul 21, 2017
Accepted (ET)
Jul 24, 2017 · 5:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001113148
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 21, 2017 | A | 85,800 | $0.00 | A | 535,020 | D | |
| Common Stock | holding | — | — | — | 12,391 | I | 401(k) |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares from a grant of performance-based restricted stock on July 22, 2016. Upon the determination by the Compensation Committee of our Board of Directors, such shares vested on July 21, 2017.